Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Aug 10;32(23):2456-62.
doi: 10.1200/JCO.2013.53.4115. Epub 2014 Jun 30.

Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer

Hiran C Fernando  1 , Rodney J Landreneau  2 , Sumithra J Mandrekar  2 , Francis C Nichols  2 , Shauna L Hillman  2 , Dwight E Heron  2 , Bryan F Meyers  2 , Thomas A DiPetrillo  2 , David R Jones  2 , Sandra L Starnes  2 , Angelina D Tan  2 , Benedict D T Daly  2 , Joe B Putnam Jr  2
Affiliations
Clinical Trial

Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer

Hiran C Fernando et al. J Clin Oncol. .

Abstract

Purpose: A major concern with sublobar resection (SR) for non-small-cell lung cancer (NSCLC) is high local recurrence (LR). Adjuvant brachytherapy may reduce LR This multicenter randomized trial compares SR to SR with brachytherapy (SRB).

Patients and methods: High-risk operable patients with NSCLC ≤ 3 cm were randomly assigned to SR or SRB. The primary end point was time to LR, where LR included recurrence at the staple line (local progression), in the primary tumor lobe away from the staple line, and in ipsilateral hilar nodes. The trial was designed to have a 90% power to detect a hazard ratio (HR) of 0.315 in favor of SRB, using a one-sided type I error rate of 0.05 with a sample size of 100 eligible patients in each arm.

Results: Two hundred twenty-four patients were randomly assigned; 222 patients were evaluable for intent-to-treat analysis. Median age was 71 years (range, 49 to 87 years). No differences were found in baseline characteristics. Median follow-up time was 4.38 years (range, 0.04 to 5.59 years). There was no difference in time to LR (HR, 1.01; 95% CI, 0.51 to 1.98; log-rank P = .98) or in the types of LR. Local progression occurred in only 17 (7.7%) of 222 patients. In patients with potentially compromised margins (margin < 1 cm, margin-to-tumor ratio < 1, positive staple line cytology, wedge resection, nodule size > 2.0 cm), SRB did not reduce LR, although trends favored the SRB arm. This was most marked in 14 patients with positive staple line cytology (HR, 0.22; P = .24). Three-year overall survival rates were similar for patients in the SR (71%) and SRB (71%) arms (P = .97).

Conclusion: Brachytherapy did not reduce LR after SR. This finding may have been related to closer attention to parenchymal margins by surgeons participating in this study.

Trial registration: ClinicalTrials.gov NCT00107172.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
CONSORT diagram. CT, computed tomography; IRB, institutional review board; NSCLC, non–small-cell lung cancer.
Fig 2.
Fig 2.
Pattern of local recurrence and cumulative incidence graph by arm for local recurrence with death or regional or distant recurrence as competing events in the intent-to-treat cohort. AnyLR, any local recurrence; LProgStpLine, local progression at staple line; LRAwayStpLine, lobar recurrence away from the staple line; N1R, nodal (N1) recurrence; SR, sublobar resection; SRB, sublobar resection with brachytherapy.
Fig 3.
Fig 3.
Kaplan-Meier curves for overall survival in the intention-to-treat cohort. NR, not reached; SR, sublobar resection; SRB, sublobar resection with brachytherapy.
Fig A1.
Fig A1.
Cumulative incidence graph by arm for local recurrence or death with regional or distant recurrence as competing events in the intention-to-treat cohort. NR, not reached; SR, sublobar resection; SRB, sublobar resection with brachytherapy.
Fig A2.
Fig A2.
Pattern of local recurrence and cumulative incidence graph by arm for local recurrence with death or regional or distant recurrence as competing events in the per-protocol cohort. AnyLR, any local recurrence; LProgStpLine, local progression at staple line; LRAwayStpLine, lobar recurrence away from the staple line; N1R, nodal (N1) recurrence; SR, sublobar resection; SRB, sublobar resection with brachytherapy.
Fig A3.
Fig A3.
Cumulative incidence graph by arm for local recurrence or death with regional or distant recurrence as competing events in the per-protocol cohort. NR, not reached; SR, sublobar resection; SRB, sublobar resection with brachytherapy.
Fig A4.
Fig A4.
Kaplan-Meier curves for overall survival in the per-protocol cohort. NR, not reached; SR, sublobar resection; SRB, sublobar resection with brachytherapy.
See this image and copyright information in PMC

Comment in

References

    1. Ginsberg RJ, Rubenstein LV. Randomized trial of lobectomy versus limited resection for T1NO non-small cell lung cancer. Ann Thorac Surg. 1995;60:615–623. - PubMed
    1. Shennib H, Bogart J, Herndon JE, et al. Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: The Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study. J Thorac Cardiovasc Surg. 2005;129:813–818. - PubMed
    1. d'Amato TA, Galloway M, Szydlowski G, et al. Intraoperative brachytherapy following thoracoscopic wedge resection of stage I lung cancer. Chest. 1998;114:1112–1115. - PubMed
    1. Lee W, Daly BD, DiPetrillo TA, et al. Limited resection for non-small cell lung cancer: Observed local control with implantation of I-125 brachytherapy seeds. Ann Thorac Surg. 2003;75:237–243. - PubMed
    1. Fernando HC, Santos RS, Benfield JR, et al. Lobar and sublobar resection with and without brachytherapy for small stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;129:261–267. - PubMed

Publication types

Associated data